Clinical trials: Ovarian Cancer, Epithelial, open to volunteers
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
BRCA1 Mutation, BRCA2 Mutation
Genetic Education in BRCA Families
The primary goal of this research is to test a web-based genetic education intervention that is designed to educate men and women from hereditary cancer families about the personal relevance of genetic testing in order to help…
- Trial name
- NCT03544983
- Testing
- Web + Streamlined Telephone Genetic Information
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Georgetown University
Breast Cancer, Non Small Cell Lung Cancer
Minimal Residual Disease in Solid Malignancies
The IMRD study is a single-centre, prospective observational study which will investigate the rate of ctDNA (circulating tumor DNA) detection from the start of adjuvant therapy following curative-intent surgery.
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer, High Grade Serous Ovarian Cancer
- Trial name
- IMRD (NCT07268469)
- Testing
- ctDNA detection
- Volunteers
- 840 people
- Sponsor
- European Institute of Oncology
Ovarian Cancer
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
At present, the treatment of recurrent ovarian cancer after PARP inhibitor therapy is quite challenging, and there is no research on the application of hyperthermic intraperitoneal chemotherapy(HIPEC) for the above-mentioned…
- Trial name
- NCT06544460
- Testing
- Secondary cytoreduction, Hyperthermic intraperitoneal chemotherapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Ovarian Epithelial Cancer
Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer
Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.
- Trial name
- Melisa-II (NCT05937620)
- Testing
- 99mTC nanocolloid albumin injection, ICG injection
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Recurrent Ovarian Cancer
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.
- Trial name
- NCT07651124
- Testing
- autologous tumor-infiltrating lymphocytes
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Yong Wha Moon
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Cancer, Solid Tumor
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Solid tumors pose significant challenges in current therapeutic approaches. Targeted therapy has emerged as a promising avenue, aiming to enhance treatment efficacy while minimizing adverse effects.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Breast Cancer
- Trial name
- PTST_PALBEVA (NCT06307249)
- Testing
- SNP, Palbociclib 125mg, Bevacizumab
- Where
- 2 sites in Lebanon
- Volunteers
- 50 people
- Sponsor
- Lebanese University
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Ovarian Germ Cell Cancer, Ovarian Neoplasms
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian…
- Conditions
- Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer
- Trial name
- MOGCT-01 (NCT02429687)
- Testing
- Paclitaxel, Carboplatin, Bleomycin
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Beihua Kong
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Surgery for Relapsed Ovarian Cancer in Precision
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06602063
- Testing
- surgery/chemotherapy, Iparomlimab/Tuvonralimab
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Ovarian Cancer, Mesothelioma
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
- Conditions
- Ovarian Cancer, Mesothelioma, Colon Cancer
- Trial name
- NCT07420010
- Testing
- KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)
- Volunteers
- 24 people
- Sponsor
- Weijia Fang, MD
Rectal Cancer, Colon Cancer
Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France. Surgical resection is a crucial step in the therapeutic management of colorectal cancers.
- Conditions
- Rectal Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT07098182
- Testing
- Clamping and restauration of arterial blood of the inferior mesenteric artery
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Ovarian Cancer, Chemotherapeutic Toxicity
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy.
- Trial name
- NCT05921149
- Testing
- Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Endeavor Health
Breast Cancers, Ovarian Cancers
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
- Trial name
- GENEPSO (NCT03667417)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Institut Paoli-Calmettes
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.
- Trial name
- ETC-159-02 (NCT06513624)
- Testing
- ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid
- Where
- 2 sites in Singapore
- Volunteers
- 16 people
- Sponsor
- National University Hospital, Singapore
Ovarian Cancer
The Role of CircDENND4C in Epithelial Ovarian Cancer
circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs [8], are involved in the regulation of various biological functions.
- Trial name
- NCT06617585
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Ovarian Cancer
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer.
- Trial name
- PARIB-OLD-PRO² (NCT06572735)
- Testing
- QoL surveys, Geriatric assessment (G-CODE), Blood sampling
- Where
- 16 sites in France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Ovarian Cancer, Differentiating
The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer
At present, there is a lack of effective screening methods. It is urgent to explore new non-invasive detection methods for early diagnosis of epithelial ovarian cancer and non-invasive differentiation methods for benign and…
- Conditions
- Ovarian Cancer, Differentiating, Diagnosis
- Trial name
- NCT05931055
- Testing
- Fragmentomics
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital